Inhibition of MST1/2 kinases of the Hippo signaling pathway enhances anti-tumor chemotherapy of hematological cancers
- Авторлар: Stepchenko A.G.1, Ilyin Y.V.1, Georgieva S.G.1, Pankratova E.V.1
-
Мекемелер:
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
- Шығарылым: Том 520, № 1 (2025)
- Беттер: 133-138
- Бөлім: Articles
- URL: https://modernonco.orscience.ru/2686-7389/article/view/682064
- DOI: https://doi.org/10.31857/S2686738925010227
- EDN: https://elibrary.ru/tbcjdm
- ID: 682064
Дәйексөз келтіру
Аннотация
One of the main reasons that significantly limit the effectiveness of antitumor chemotherapy is the primary and acquired resistance of tumor cells to drugs during treatment, as well as severe side effects depending on the dose of the drug. An increase in the effectiveness of chemotherapy drugs can be achieved through their combination with substances that modulate the work of cell signaling pathways. In this work, we show that the substance XMU-MP-1, an inhibitor of key MST1/2 kinases of the Hippo signaling pathway, enhances the antitumor activity of two genotoxic chemotherapy drugs etoposide and cisplatin against Burkitt’s Namalwa B-cell lymphoma. X MU-MP-1 increases their cytotoxicity and significantly reduces CTD50. Thus, the effectiveness of chemotherapy drugs can be significantly increased and the therapeutic effect can be achieved at a lower concentration, which reduces the likelihood of life-threatening side effects.
Негізгі сөздер
Толық мәтін

Авторлар туралы
A. Stepchenko
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
Email: pank@eimb.ru
Ресей, Moscow
Yu. Ilyin
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
Email: pank@eimb.ru
академик РАН
Ресей, MoscowS. Georgieva
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
Email: pank@eimb.ru
Academician of the RAS
Ресей, MoscowE. Pankratova
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
Хат алмасуға жауапты Автор.
Email: pank@eimb.ru
Center for Precision Genome Editing and Genetic Technologies for Biomedicine
Ресей, MoscowӘдебиет тізімі
- Клинические рекомендации по диагностике и лечению лимфомы Беркитта. Коллектив авторов под руководством академика В.Г. Савченко, профессора И.В. Поддубной. Рекомендации утверждены на II Конгрессе гематологов. Национальное гематологическое общество. Российское профессиональное общество онкогематологов. 2014 г.
- Bae J.S., Kim S.M., Lee H. The Hippo signaling pathway provides novel anti-cancer drug targets // Oncotarget. 2017. 8(9). Р. 16084–16098. doi: 10.18632/oncotarget.14306
- Wang J., Liu S., Heallen T., Martin J.F. The Hippo pathway in the heart: pivotal roles in development, disease, and regeneration // NatRevCardiol. 2018. 15(11). Р. 672–684.
- Zheng Y., Pan D. The Hippo Signaling Pathway in Development and Disease // Dev Cell. 2019. 50(3). Р. 264–282.
- Fu M., Hu Y., Lan T., et al. The Hippo signalling pathway and its implication sin human health and diseases // Signal Transduct Target Ther. 2022. 7(1). Р. 376. Published 2022. Nov 8.
- Liu H., Du S., Lei T., et al. Multifaceted regulation and functions of YAP/TAZ in tumors (Review) // Oncol Rep. 2018. 40(1). Р. 16–28.
- Zanconato F., Cordenonsi M., Piccolo S. YAP/TAZ at the Roots of Cancer // CancerCell. 2016. 29(6). Р. 783–803.
- Патент CN103429582A (заявка 2012-03-02; публикация 2013-12-04) “MST1 kinase inhibitors and method of use thereof”
- Fan F., He Z., Kong L.L., et al. Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration // Sci Transl Med. 2016. 8(352). Р. 352ra108.
- Cottini F., Hideshima T., Xu C., et al. Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers // Nat Med. 2014. 20(6). Р. 599–606.
- Triastuti E., Nugroho A.B., Zi M., et al. Pharmacological inhibition of Hippo pathway, with the novel kinase inhibitor XMU-MP-1, protects the heart against adverse effects during pressure overload // Br J Pharmacol. 2019. 176(20). Р. 3956–3971.
- Ueda Y., Kondo N., Kinashi T. MST1/2 Balance Immune Activation and Tolerance by Orchestrating Adhesion, Transcription, and Organelle Dynamics in Lymphocytes // Front Immunol. 2020. 11. Р. 733. Published 2020, May 6.
- Патент CN114366750B (приоритет 2021-12-22; публикация 2022-11-25)
- Zhou X., Wang H., Li D., Song N., Yang F., Xu W. MST1/2 inhibitor XMU-MP-1 alleviates the injury induced by ionizing radiation in haematopoietic and intestinal system // J Cell Mol Med. 2022. Mar. 26(5). Р. 1621–1628.
Қосымша файлдар
